Sept 28 (Reuters) - J&J:
* Johnson & Johnson and Crucell announce strategic collaboration to develop
innovative products, including therapies for influenza prevention and
treatment
* Says has also purchased 14.6 million newly issued ordinary shares of Crucell
* Says immediate focus of collaboration will be development and
commercialization of a universal monoclonal antibody product
* Says purchase for an aggregate purchase price of Euro 301.8 million
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Johnson & Johnson and Crucell announce strategic collaboration to develop
innovative products, including therapies for influenza prevention and
treatment
* Says has also purchased 14.6 million newly issued ordinary shares of Crucell
* Says immediate focus of collaboration will be development and
commercialization of a universal monoclonal antibody product
* Says purchase for an aggregate purchase price of Euro 301.8 million
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
